RIBOMIC INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82 JPY | 0.00% |
|
+1.23% | -24.07% |
| Sales 2022 | 80M 512K 42.7M | Sales 2023 | 65M 416K 34.69M | Capitalization | 6.71B 42.93M 3.58B |
|---|---|---|---|---|---|
| Net income 2022 | -1.68B -10.77M -899M | Net income 2023 | -1.65B -10.58M -882M | EV / Sales 2022 | 16.2 x |
| Net cash position 2022 | 4.7B 30.08M 2.51B | Net cash position 2023 | 4.32B 27.67M 2.31B | EV / Sales 2023 | 36.7 x |
| P/E ratio 2022 |
-3.5
x | P/E ratio 2023 |
-3.54
x | Employees | 25 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.31% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | +1.23% | ||
| Current month | -11.83% | ||
| 1 month | -11.83% | ||
| 3 months | -24.77% | ||
| 6 months | -34.92% | ||
| Current year | -24.07% |
1 week
81.00
100.00
1 month
79.00100.00
Current year
79.00121.00
1 year
79.00184.00
3 years
79.00944.00
5 years
79.001 109.00
10 years
79.002 078.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
| President | 76 | 01/03/01 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/15/01 | |
| President | 76 | 01/03/01 | |
Emiko Nakamura
BRD | Director/Board Member | 45 | 01/03/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 82 | 0.00% | 205,700 |
| 25/24/25 | 82 | -2.38% | 332,700 |
| 24/24/24 | 84 | +1.20% | 3,846,700 |
| 23/24/23 | 83 | +1.22% | 117,300 |
| 22/24/22 | 82 | +1.23% | 111,500 |
Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST
More quotes
RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
Calendar
14/05/2024
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -24.07% | 18.75M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.49% | 22.15B | |
| -17.37% | 21.02B | |
| -8.61% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 4591 Stock
